Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Sarcoidosis, Pulmonary: early-phase trial registry
3 of 4 indexed Sarcoidosis, Pulmonary trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Sarcoidosis, Pulmonary: 4 US clinical trials tracked, 3 recruiting.
Sarcoidosis, Pulmonary is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is National Heart, Lung, and Blood Institute (NHLBI), running 1 of these trials.
Enrollment posture brief
Registry condition sarcoidosis-pulmonary
OPEN 3 | RECR 75% | LATE 0 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Sarcoidosis, Pulmonary lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Sarcoidosis, Pulmonary on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Sarcoidosis, Pulmonary is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Risk Indicators of Sarcoidosis Evolution-Unified Protocol
University of California, San Francisco
NCT05567133
Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy
George Washington University
NCT05374447
Feasibility of Semaglutide in Advanced Lung Disease
University of Pennsylvania
NCT05746039
Atorvastatin to Treat Pulmonary Sarcoidosis
National Heart, Lung, and Blood Institute (NHLBI)
NCT00279708
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Sarcoidosis, Pulmonary records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Sarcoidosis, Pulmonary trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Sarcoidosis, Pulmonary page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Sarcoidosis, Pulmonary trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Heart, Lung, and Blood Institute (NHLBI) sponsors the most Sarcoidosis, Pulmonary trials on record, review their full trial history before evaluating a specific study. See National Heart, Lung, and Blood Institute (NHLBI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sarcoidosis, Pulmonary condition card totals 4 registered trials; most-linked intervention Placebo Oral Tablet; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.